Initial Medical Exam: A complete history & physical exam: ... Exam of blood, nervous system, GI system, & cardiovascular system should be stressed. Skin should be exam for evidence of chronic disorders. ... A complete blood count should be performed, including red cell count, a white cell count, a differential count of stained smear, as well as hemoglobin & hematocrit. Periodic Medical Exam: The ... /initial med exam/ should be repeated on an annual basis. Methemoglobin determinations should be performed if overexposure is suspected or signs & symptoms of toxicity occur. /Nitrotoluene/
... The onset of symptoms of methemoglobinemia is insidious and may be delayed up to 4 hours; headache is commonly the first symptom and may become quite intense as the severity of methemoglobinemia progresses. ... Cyanosis develops early in the course of intoxication, first the lips, the nose, and the ear lobes, and is usually recognized by fellow workers ... Until the methemeglobinemia concentration approaches approximately 40%, the individual usually feels well, has no complaints, and will insist that nothing is wrong. ... Over 40% ... weakness and dizziness; at up to 70% ... there may be ataxia, dyspnea on mild exertion, tachycardia, nausea, vomiting, and drowsiness. /Nitrotoluene/
THE COMPARATIVE TOXICITY OF 2-CHLORO-4-NITROTOLUENE (CNT) WAS INVESTIGATED IN STARLINGS, CHICKENS AND RATS. ADULT STARLINGS, 4-WK OLD NEW HAMPSHIRE CHICKENS & MALE SPRAGUE DAWLEY RATS WERE GAVAGED WITH DIFFERENT DOSES OF CNT SUSPENDED IN 2.5% CARBOXYMETHYL CELLULOSE. STARLINGS WERE FOUND TO BE EXTREMELY RESISTANT TO CNT TOXICITY, NO MORTALITY WAS OBSERVED AT THE 4000 MG/KG DOSE. THE APPROXIMATE LD50 DOSE OF CNT IN CHICKENS WAS BETWEEN 100 & 500 MG/KG. THE LD50 DOSE IN RATS WAS 2520 MG/KG. SINCE THE AMINO DERIVATIVE OF THE RELATED CMPD, 3-CHLORO-P-TOLUIDINE, IS MORE TOXIC IN STARLINGS, CHICKENS AND RATS THAN ITS NITRO DERIVATIVE, IT THEN INDICATES THAT THE BASAL ACTIVITY OF NITRO-REDUCTASE IN THESE ANIMALS IS PROBABLY ONE OF THE IMPORTANT DETERMINANTS FOR CNT TOXICITY.
1.周国泰,化学危险品安全技术全书,化学工业出版社,1997 2.国家环保局有毒化学品管理办公室、北京化工研究院合编,化学品毒性法规环境数据手册,中国环境科学出版社.1992 3.Canadian Centre for Occupational Health and Safety,CHEMINFO Database.1998 4.Canadian Centre for Occupational Health and Safety, RTECS Database, 1989
The development of transition metal intermetallic compounds, in which active sites are incorporated in lattice frameworks, has great potential for modulating the local structure and the electronic properties of active sites, and enhancing the catalytic activity and stability. Here we report that a new copper-based intermetallicelectridecatalyst, LaCu0.67Si1.33, in which Cu sites activated by anionic
过渡金属间化合物的开发,其中活性位点并入晶格骨架中,具有很大的潜力来调节活性位点的局部结构和电子性质,并增强催化活性和稳定性。在这里,我们报道了一种新型的铜基金属间电催化剂LaCu 0.67 Si 1.33,其中具有低功函的阴离子电子激活的Cu位原子原子地分散在晶格骨架中,并提供硝基芳烃的选择性加氢,其营业额高40倍以上频率(TOF高达5084 h –1),而不是经过深入研究的金属负载催化剂。利用同位素效应的动力学分析表明,氢键的裂解是决定速率的步骤。出乎意料的是,LaCu 0.67 Si 1.33的高载流子密度和低逸出功(LWF)特性使得能够以极低的活化能(E a = 14.8 kJ·mol –1)活化氢分子。此外,LaCu 0.67 Si 1.33的高氧亲合力可实现通过硝基优先吸附硝基芳烃表面,导致高化学选择性。本发明的有效催化剂可以进一步引发具有高活性的其他含氧官能团例如醛和酮的氢化
Synthesis ofN-Phenyl-N′-pyrimidylurea Derivatives by Selenium- or Selenium Dioxide-Catalyzed Reductive Carbonylation of Nitroaromatics
作者:Jinzhu Chen、Gang Ling、Shiwei Lu
DOI:10.1002/ejoc.200300127
日期:2003.9
N-phenyl-N′-pyrimidylureaderivatives were synthesized in moderate-to-good yields by one-pot reductivecarbonylation of nitroaromatics using selenium or selenium dioxide as the catalyst, aminopyrimidine derivatives as co-reagents, and carbon monoxide as the carbonyl source. The reaction parameters were investigated, as was the reusability of the catalysts. We found that selenium- or selenium dioxide-catalyzed
[EN] QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER<br/>[FR] DERIVES DE QUINAZOLINE A UTILISER CONTRE LE CANCER
申请人:ASTRAZENECA AB
公开号:WO2006040526A1
公开(公告)日:2006-04-20
The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of p, R1, q, R2, R3, R4, R5, Ring A, X1, R6, r and R7 has any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.
IRON OXIDE SUPPORTED RHODIUM CATALYST FOR NITROARENE REDUCTION
申请人:King Fahd University of Petroleum and Minerals
公开号:US20200298212A1
公开(公告)日:2020-09-24
A supported catalyst having rhodium particles with an average diameter of less than 1 nm disposed on a support material containing magnetic iron oxide (e.g. Fe
3
O
4
). A method of producing the supported catalyst and a process of reducing nitroarenes to corresponding aromatic amines employing the supported catalyst with a high product yield are also described. The supported catalyst may be recovered with ease using an external magnet and reused.
Dichlorine monoxide: a powerful and selective chlorinating reagent
作者:F. D. Marsh、W. B. Farnham、D. J. Sam、B. E. Smart
DOI:10.1021/ja00381a032
日期:1982.8
-Dichlorine monoxide is a powerful and selective reagent for either side chain or ring chlorination of deactivated aromatic substrates. It gives excellent product yields under mild conditions where conventional reagents fail or require harsh conditions. The mechanistic aspects of the dichlorine monoxide reactions have been probed using linear free-energy relationships, isotope effects and competitive